Anastasia S. Lambrou

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022

Anastasia S. Lambrou, Philip Shirk, Molly Steele et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 206 citations · Full text

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Ruth Link‐Gelles, Allison Avrich Ciesla, Josephine Mak et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 159 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +23

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages — United States, January 2022–May 2023

C. Kevin, Philip Shirk, Anastasia S. Lambrou et al. · MMWR Morbidity and Mortality Weekly Report · 2023 · 98 citations · Full text

Virus Epidemiology, Viral Diagnostics, Immunodeficiencies +21

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024

C. Kevin, Juan E. De Castro, Anastasia S. Lambrou et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 43 citations · Full text

Viral Diagnostics, Genetics, Immunodeficiencies +19

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

Kaitlin Rainwater‐Lovett, John T. Redd, Miles Stewart et al. · Open Forum Infectious Diseases · 2021 · 32 citations · Full text